Reflections on the importance of factor VIII and Von Willebrand factor pharmacokinetics in the safety and efficacy of current Von Willebrand factor concentrates

Le résumé fourni par la source

Prophylaxis in von Willebrand disease is addressed, focusing on the composition and efficacy of von Willebrand factor concentrates.Three products with different characteristics in terms of their origin and composition (Veyvondi ® , Wilate ® , and Wilfact ® ) are compared, highlighting their differences in weekly consumption, infusions and thrombotic events.The results indicate that Wilate ® has a lower weekly intake and comparable efficacy in reducing bleeding.The accumulation of factor VIII and its relationship with thrombotic risk are discussed, underlining the importance of precise dosing to maximize efficacy and minimize safety and economic risks.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.